Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
Chemicals AmericaChemicals America
Not Confirmed
Not Confirmed
29-31 July, 2025
Vietnam Medi-Pharm Exp...Vietnam Medi-Pharm Expo
Not Confirmed
Not Confirmed
31 July-02 August, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
Chemicals AmericaChemicals America
Industry Trade Show
Not Confirmed
29-31 July, 2025
Vietnam Medi-Pharm Exp...Vietnam Medi-Pharm Expo
Industry Trade Show
Not Confirmed
31 July-02 August, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
28 Jun 2025
// ENDPTS
https://endpoints.news/vor-bio-bounces-back-with-remegen-autoimmune-deal-175m-private-placement/
17 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/remegens-telitacicept-rc18-received-orphan-drug-designation-from-ema-for-myasthenia-gravis-302484029.html
27 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/remegen-telitacicept-for-the-treatment-of-generalized-myasthenia-gravis-approved-in-china-302465629.html
13 May 2025
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/pfizer-partner-remegen-says-her2-adc-prolongs-life-china-trial-newly-diagnosed-bladder
14 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/asco-guremegen-announced-highly-encouraging-data-from-the-phase-ii-clinical-trial-evaluating-disitamab-vedotin-plus-immunotherapy-as-perioperative-regimen-for-bladder-cancer-302377461.html
29 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/remegen-announces-the-acceptance-of-the-marketing-application-of-telitaccept-for-the-treatment-of-myasthenia-gravis-in-china-302289346.html
ABOUT THIS PAGE